Cancer Stem Cell News Volume 3.09 | Mar 12 2014

Cancer Stem Cell News 3.09 March 12, 2014

Cancer Stem Cell News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

Several FDA-Approved Anti-Cancer Drugs Induce Stem Cell Tumors, Perhaps Thwarting Therapy
Using a new approach to systematically test chemotherapy drugs in an unusual animal model, researchers report that several have a serious side effect: inducing hyper proliferation in stem cells that could lead to tumor recurrence. [Press release from the University of Massachusetts Amherst discussing online prepublication in the Proceedings of the National Academy of Sciences, USA] Press Release | Abstract
Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells

PUBLICATIONS (Ranked by impact factor of the journal)
Sox2 Is Required to Maintain Cancer Stem Cells in a Mouse Model of High-Grade Oligodendroglioma
Researchers investigated the requirement for Sox2 in neural cancer stem-like cells using a conditional genetic deletion mutant in a mouse model of platelet-derived growth factor-induced malignant oligodendroglioma. [Cancer Res] Abstract

Endothelial Cells Promote Stem-Like Phenotype of Glioma Cells through Activating Hedgehog Pathway
Investigators observed that CD133+ glioma stem cells were located closely to Shh+ endothelial cells in the specimens of human primary glioblastoma multiforme. [J Pathol] Abstract | Full Article

p63 Isoforms Regulate Metabolism of Cancer Stem Cells
The authors investigated the cellular signals regulated by p63 isoforms containing (TA) or lacking (ΔN) the N-terminal transactivation domain in a model of epithelial-cancer stem cells. They used colon cancer stem cells, over-expressing either TAp63 or ΔNp63 isoforms, to carry out a proteomic study by chemical labeling approach coupled to network analysis. [J Proteome Res] Abstract

PPARγ and RXR Ligands Disrupt the Inflammatory Cross-Talk in the Hypoxic Breast Cancer Stem Cells Niche
Investigators found that 6-OH-11-O-hydroxyphenanthrene potentiates the ability of pioglitazone to hamper the mammospheres-forming capability of human breast tumors and MCF7 cancer cells, reducing the expression of cancer stem cell regulatory genes. [J Cell Physiol] Abstract

The MicroRNA miR-34a Inhibits Non-Small Cell Lung Cancer (NSCLC) Growth and the CD44hi Stem-Like NSCLC Cells
Scientists showed that transfection of synthetic microRNA-34a (miR-34a), but not the negative control miRNA oligonucleotides in three NSCLC cell lines, i.e., A549, H460, and H1299, inhibited their holoclone formation, clonogenic expansion, and tumor regeneration in vivo. [PLoS One] Full Article

Natural Compounds’ Activity against Cancer Stem-Like or Fast-Cycling Melanoma Cells
Investigators analyzed 120 compounds from The Natural Products Set II to identify compounds active against melanoma populations grown in an anchorage-independent manner and enriched with cells exerting self-renewing capacity. [PLoS One] Full Article

Pharmacological Inhibition of Poly(ADP-Ribose) Polymerase-1 Modulates Resistance of Human Glioblastoma Stem Cells to Temozolomide
Researchers investigated whether poly(ADP-ribose) polymerase inhibitors may restore glioblastoma stem cell sensitivity to temozolomide or may be effective as monotherapy. [BMC Cancer] Abstract | Full Article

Thioridazine, an Antipsychotic Drug, Elicits Potent Antitumor Effects in Gastric Cancer
Thioridazine, an antipsychotic drug, has been reported to induce apoptosis in various types of cancer cells, with specificity on targeting cancer stem cells. Investigators examined the ability of thioridazine to induce cell death in the gastric cancer cell lines NCI-N87 and AGS, and detected its in vivo tumor inhibition capacity. [Oncol Rep] Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack - Get Yours

Cancer Stem Cells and Radioresistance
Despite continuous improvements, tumor recurrence and therapy resistance still occur in a high proportion of patients. One underlying reason for this radioresistance might be attributable to the presence of cancer stem cells (CSC). The purpose of this review is to discuss CSC-specific mechanisms that confer radiation resistance. [Int J Radiat Biol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Attend ISCT 2014 in Paris, France!

NW Bio Receives Recommendation to Continue with Phase III GBM Brain Cancer Trial Based on Data Safety Monitoring Board’s Safety Review
Northwest Biotherapeutics (NW Bio) announced that the Data Safety Monitoring Board has made an unblinded review of the safety data for the company’s ongoing international Phase III GBM Trial, and has recommended that the trial continue as planned. [Northwest Biotherapeutics Inc.] Press Release

Timothy J. Barberich Joins Verastem Board of Directors
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the appointment of Timothy J. Barberich to its Board of Directors. [Verastem, Inc.]
Press Release

Stem Cell Therapeutics Strengthens Its Board of Directors
Stem Cell Therapeutics Corp., an immuno-oncology company developing cancer stem cell-related therapeutics, announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the company’s Board of Directors. [Stem Cell Therapeutics Corp.] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW NYSTEM 2014 Meeting
May 29-30, 2014
New York City, United States

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Tenure-Track Faculty Position – Cancer Biology and Evolution (Moffitt Cancer Center)

NEW Postdoctoral Position – Glioblastoma, Oncolytic Virus and Cell Signaling (Ohio State University)

NEW Postdoctoral Research Fellow – Cancer Bioinformatics (Karolinska Institutet)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Scientist – Small Cell Lung Cancer Circulating Tumor Cell Derived Explant Tumor Models (Cancer Research UK Manchester Institute)

Faculty Position – Cancer Biology and Evolution (Moffitt Cancer Center & Research Institute)

Postdoctoral Position – Molecular Mechanisms of Cell Division (Memorial Sloan Kettering Cancer Center)

Postdoctoral Position – Stem Cell Signaling and Epigenetics (Fondazione Istituto Nazionale Genetica Molecolare)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us